FilingReader Intelligence
Yantai Dongcheng subsidiary secures radioactive pharmaceutical production license
July 28, 2025 at 10:30 AM UTC•By FilingReader AI
Yantai Dongcheng Biochemicals' subsidiary Yantai Xinkesida Pharmaceutical Technology has obtained a Radioactive Pharmaceutical Production License valid until July 2030.
The company said the development paves the way for commercialization upon marketing approval, though it is not expected to significantly impact current performance.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
SZSE:002675•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Yantai Dongcheng Biochemicals publishes news
Free account required • Unsubscribe anytime